bioAffinity Technologies (BIAF) Projected to Post Quarterly Earnings on Monday

bioAffinity Technologies (NASDAQ:BIAF) will likely be announcing its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($2.70) per share and revenue of $1.5530 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 31, 2026 at 12:30 PM ET.

bioAffinity Technologies (NASDAQ:BIAF) last released its earnings results on Friday, March 13th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.70) by $1.59. bioAffinity Technologies had a negative return on equity of 301.67% and a negative net margin of 241.93%.The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $1.55 million.

bioAffinity Technologies Stock Performance

Shares of NASDAQ BIAF opened at $2.73 on Monday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.58 and a current ratio of 2.60. The stock has a 50 day moving average price of $1.29 and a 200 day moving average price of $2.25. The stock has a market capitalization of $12.29 million, a PE ratio of -0.17 and a beta of 2.42. bioAffinity Technologies has a 52 week low of $0.69 and a 52 week high of $46.53.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Scientech Research LLC bought a new stake in bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned about 0.46% of bioAffinity Technologies as of its most recent filing with the Securities and Exchange Commission. 1.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Reduce”.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.